Human APRIL Recombinant Protein Data Sheet

Total Page：16

File Type：pdf, Size：1020Kb

Human APRIL Recombinant Protein Data Sheet

Human APRIL (recombinant) Alias: TNFSF13 Catalog #: 6455 Size: 5 ug Research Use Only Molecular Weight: 16.4 kDa Source: Yeast. Recombinant Human APRIL (TNFSF13) was produced in yeast and, therefore, does not have endotoxin. It is naturally folded and post-translationally modified. Formulation: Lyophilized without carrier protein. Purity: >95% as visualized by SDS-PAGE analysis. Purification: Ion-exchange chromatography. Bioactivity: In testing Entrez Gene ID: 8741 Number of Amino Acids: 146 Amino Acid Sequence: AVLTQKQKKQ HSVLHLVPIN ATSKDDSDVT EVMWQPALRR GRGLQAQGYG VRIQDAGVYL LYSQVLFQDV TFTMGQVVSR EGQGRQETLF RCIRSMPSHP DRAYNSCYSA GVFHLHQGDI LSVIIPRARA KLNLSPHGTF LGFVKL (146) Country of Origin: USA Reconstitution: Reconstitute with sterile phosphate-buffered saline containing at least 0.1% carrier protein. Stability and Storage: Stable for up to twelve months from date of receipt at -20˚C. Stable for at least 3 months when stored in working aliquots with a carrier protein at -20˚C. Avoid repeated freeze/thaw cycles. Applications: The APRIL protein can be used in cell culture, as an APRIL ELISA Standard, and as a Western Blot Control. Background: Tumor necrosis factor ligand superfamily member 13 (TNFSF13), also known as a proliferation-inducing ligand (APRIL), is a member of the tumor necrosis factor (TNF) ligand family. Nineteen cytokines have been identified as part of the TNF family on the basis of sequence, functional, and structural similarities. Family members include TNF beta (TNFSF1), TNF alpha (TNFSF2), Lymphotoxin beta (TNFSF3), OX40 Ligand (TNFSF4), CD40 Ligand (TNFSF5), Fas Ligand (TNFSF6), CD27 Ligand (TNFSF7), CD30 Ligand (TNFSF8), 4-1BB Ligand (TNFSF9), TRAIL (TNFSF10), TRANCE/RANKL (TNFSF11), TWEAK (TNFSF12), APRIL(TNFSF13), BAFF (TNFSF13B), LIGHT (TNFSF14), TL1A/VEGI (TNFSF15), and GITR Ligand (TNFSF18). APRIL/TNFSF13 is expressed by macrophages and dendritic cells. APRIL/TNFSF13 has been shown to play a role in protecting cells from undergoing apoptosis and promoting B cell development. F17-6358-4-A Data Sheet; Effective: 1/10/14; Supersedes: None; Page 1 of 1; Recombinant Human APRIL (TNFSF13) updated on: 1/29/2014.

Copy Link

Recommended publications

CD40L TNF-Related Factors BAFF, APRIL, and Lymphocytic Leukemia
Published May 16, 2012, doi:10.4049/jimmunol.1102066 The Journal of Immunology Stromal Endothelial Cells Establish a Bidirectional Crosstalk with Chronic Lymphocytic Leukemia Cells through the TNF-Related Factors BAFF, APRIL, and CD40L Montserrat Cols,* Carolina M. Barra,† Bing He,* Irene Puga,† Weifeng Xu,* April Chiu,‡ Wayne Tam,x Daniel M. Knowles,x Stacey R. Dillon,{ John P. Leonard,‖ Richard R. Furman,‖ Kang Chen,* and Andrea Cerutti*,†,# Chronic lymphocytic leukemia (CLL) is a clonal B cell disorder of unknown origin. Accessory signals from the microenvironment are critical for the survival, expansion, and progression of malignant B cells. We found that the CLL stroma included microvascular endothelial cells (MVECs) expressing BAFF and APRIL, two TNF family members related to the T cell-associated B cell-stimulating molecule CD40L. Constitutive release of soluble BAFF and APRIL increased upon engagement of CD40 on MVECs by CD40L aberrantly expressed on CLL cells. In addition to enhancing MVEC expression of CD40, leukemic CD40L induced cleavases that elicited intracellular processing of pro-BAFF and pro-APRIL proteins in MVECs. The resulting soluble BAFF and APRIL proteins delivered survival, activation, Ig gene remodeling, and differentiation signals by stimulating CLL cells through TACI, BAFF-R, and BCMA receptors. BAFF and APRIL further ampliﬁed CLL cell survival by upregulating the expression of leukemic CD40L. Inhibition of TACI, BCMA, and BAFF-R expression on CLL cells; abrogation of CD40 expression in MVECs; or suppression of BAFF and APRIL cleavases in MVECs reduced the survival and diversiﬁcation of malignant B cells. These data indicate that BAFF, APRIL, and CD40L form a CLL-enhancing bidirectional signaling network linking neoplastic B cells with the microvascular stroma.
[Show full text]
RANKL As a Novel EMT Marker 858 Cell Research (2008) 18:858-870
npg RANKL as a novel EMT marker 858 Cell Research (2008) 18:858-870. npg © 2008 IBCB, SIBS, CAS All rights reserved 1001-0602/08 $ 30.00 ORIGINAL ARTICLE www.nature.com/cr Receptor activator of NF-κB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells Valerie A Odero-Marah1, Ruoxiang Wang1, Gina Chu1, Majd Zayzafoon2, Jianchun Xu1, Chunmeng Shi1, Fray F Marshall1, Haiyen E Zhau1, Leland WK Chung1 1Molecular Urology and Therapeutics Program, Department of Urology and Winship Cancer Institute, Emory University School of Medicine, 1365B Clifton Road, NE, Atlanta, GA 30322, USA; 2Department of Pathology, University of Alabamn, Birmingham, AL 35294, USA Epithelial-mesenchymal transition (EMT) in cancer describes the phenotypic and behavioral changes of cancer cells from indolent to virulent forms with increased migratory, invasive and metastatic potential. EMT can be induced by soluble proteins like transforming growth factor β1 (TGFβ1) and transcription factors including Snail and Slug. We uti- lized the ARCaPE/ARCaPM prostate cancer progression model and LNCaP clones stably overexpressing Snail to identify novel markers associated with EMT. Compared to ARCaPE cells, the highly tumorigenic mesenchymal ARCaPM and ARCaPM1 variant cells displayed a higher incidence of bone metastasis after intracardiac administration in SCID mice. ARCaPM and ARCaPM1 expressed mesenchymal stromal markers of vimentin and N-cadherin in addition to elevated levels of Receptor Activator of NF-κB Ligand (RANKL). We observed that both epidermal growth factor (EGF) plus TGFβ1 treatment and Snail overexpression induced EMT in ARCaPE and LNCaP cells, and EMT was associated with increased expression of RANKL protein.
[Show full text]
Antagonist Antibodies Against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound S
Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2016/07/19/jpet.116.236075.DC1 1521-0103/359/1/37–44$25.00 http://dx.doi.org/10.1124/jpet.116.236075 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 359:37–44, October 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Unexpected Potency Differences between B-Cell–Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound s Amy M. Nicoletti, Cynthia Hess Kenny, Ashraf M. Khalil, Qi Pan, Kerry L. M. Ralph, Julie Ritchie, Sathyadevi Venkataramani, David H. Presky, Scott M. DeWire, and Scott R. Brodeur Immune Modulation and Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut Received June 20, 2016; accepted July 18, 2016 Downloaded from ABSTRACT Therapeutic agents antagonizing B-cell–activating factor/B- human B-cell proliferation assay and in nuclear factor kB reporter lymphocyte stimulator (BAFF/BLyS) are currently in clinical assay systems in Chinese hamster ovary cells expressing BAFF development for autoimmune diseases; belimumab is the first receptors and transmembrane activator and calcium-modulator Food and Drug Administration–approved drug in more than and cyclophilin ligand interactor (TACI). In contrast to the mouse jpet.aspetjournals.org 50 years for the treatment of lupus. As a member of the tumor system, we find that BAFF trimer activates the human TACI necrosis factor superfamily, BAFF promotes B-cell survival and receptor. Further, we profiled the activities of two clinically ad- homeostasis and is overexpressed in patients with systemic vanced BAFF antagonist antibodies, belimumab and tabalumab.
[Show full text]
Circadian Phase-Specific Degradation of the F-Box Protein ZTL Is Mediated by the Proteasome
Circadian phase-specific degradation of the F-box protein ZTL is mediated by the proteasome Woe-Yeon Kim*, Ruishuang Geng*, and David E. Somers† Department of Plant Biology͞Plant Biotechnology Center, Ohio State University, Columbus, OH 43210 Edited by Maarten J. Chrispeels, University of California at San Diego, La Jolla, CA, and approved February 3, 2003 (received for review November 14, 2002) Critical to the maintenance of circadian rhythmicity is the cyclic Materials and Methods expression of at least some components of the central oscillator. Plant and Cell Culture Growth and Maintenance. Arabidopsis High-amplitude cycling of mRNA and protein abundance, protein suspension-cultured cells were grown in 50 ml of Gamborg B5 ͞ phosphorylation and nuclear cytoplasmic shuttling have all been medium (Sigma) supplemented with 1.1 mg͞liter 2,4-D and 0.5 implicated in the maintenance of circadian period. Here we use a g͞liter MES at 22°C under continuous fluorescent white light (60 newly characterized Arabidopsis suspension cell culture to estab- ␮mol mϪ2⅐sϪ1). Cells were subcultured every 7 days at a 10-fold lish that the rhythmic changes in the levels of the clock-associated dilution with fresh medium. For circadian studies, 15 ml of F-box protein, ZTL, are posttranscriptionally controlled through 8-day-old cultures were diluted to 50 ml with fresh medium, different circadian phase-speciﬁc degradation rates. This proteol- grown in constant light for 1 day, then shifted to 12͞12 h ysis is proteasome dependent, implicating ZTL itself as substrate light͞dark cycles for 2 or 3 days before onset of treatments. for ubiquitination.
[Show full text]
(Blys) on Diabetes-Related Periodontitis
ORIGINAL RESEARCH Immunology Preliminary findings on the possible role of B-lymphocyte stimulator (BLyS) on diabetes-related periodontitis Marx Haddley Ferreira Abstract: The possible role of B-cell growth and differentiation- DRUMOND(a) related cytokines on the pathogenesis of diabetes-related periodontitis Luciano Eduardo PUHL(a) has not been addressed so far. The aim of this study was to evaluate Poliana Mendes DUARTE(b) the effects of diabetes mellitus (DM) on the gene expression of Tamires Szeremeske de proliferation-inducing ligand (APRIL) and B-lymphocyte stimulator MIRANDA(c) (BLyS), two major cytokines associated to survival, differentiation Juliana Trindade and maturation of B cells in biopsies from gingival tissue with CLEMENTE-NAPIMOGA(a) periodontitis. Gingival biopsies were obtained from subjects with Daiane Cristina PERUZZO(a) periodontitis (n = 17), with periodontitis and DM (n = 19) as well as Elizabeth Ferreira MARTINEZ(a) from periodontally and systemically healthy controls (n = 10). Gene Marcelo Henrique NAPIMOGA(a) expressions for APRIL, BLyS, RANKL, OPG, TRAP and DC-STAMP were evaluated using qPCR. The expressions APRIL, BLyS, RANKL, (a) Faculdade São Leopoldo Mandic, Instituto OPG, TRAP and DC-STAMP were all higher in both periodontitis de Pesquisas São Leopoldo Mandic, groups when compared to the control group (p < 0.05). Furthermore, Campinas, SP, Brazil. the expressions of BLyS, TRAP and RANKL were significantly higher (b) University of Florida, College of Dentistry, in the subjects with periodontitis and DM when compared to those Department of Periodontology, Gainesville, FL, USA. with periodontitis alone (p < 0.05). The mRNA levels of BLyS correlated positively with RANKL in the subjects with periodontitis and DM (c) Guarulhos University, Dental Research Division, Department of Periodontology, São (p < 0.05).
[Show full text]
Induces Antigen Presentation in B Cells Cell-Activating Factor of The
B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells This information is current as of September 27, 2021. Min Yang, Hidenori Hase, Diana Legarda-Addison, Leena Varughese, Brian Seed and Adrian T. Ting J Immunol 2005; 175:2814-2824; ; doi: 10.4049/jimmunol.175.5.2814 http://www.jimmunol.org/content/175/5/2814 Downloaded from References This article cites 54 articles, 36 of which you can access for free at: http://www.jimmunol.org/content/175/5/2814.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells1 Min Yang,* Hidenori Hase,* Diana Legarda-Addison,* Leena Varughese,* Brian Seed,† and Adrian T.
[Show full text]
APRIL Multimeric Recombinant Protein Cat
APRIL multimeric Recombinant Protein Cat. No.: 90-273 APRIL multimeric Recombinant Protein Specifications SPECIES: Human, Mouse SOURCE SPECIES: HEK293 cells The extracellular domain of mouse APRIL (aa 88-232) is fused at the N-terminus to mouse SEQUENCE: ACRP30headless (aa 18-110) and a DDDDK-tag. FUSION TAG: DDDDK Tag TESTED APPLICATIONS: APPLICATIONS: This recombinant proteins is for research use only. Properties >95% (SDS-PAGE). PURITY: Endotoxin level is less than 0.02EU/ μg purified protein (LAL test; Lonza). PHYSICAL STATE: Lyophilized BUFFER: Contains PBS + 0.5% Trehalose. Reconstitute with 100 μl sterile water. CONCENTRATION: 0.1mg/ml after reconstitution. STORAGE CONDITIONS: Stable for at least 6 months after receipt when stored at -20˚C. September 25, 2021 1 https://www.prosci-inc.com/april-multimeric-recombinant-protein-90-273.html Additional Info OFFICIAL SYMBOL: Tnfsf13 ACRP30headless:APRIL, ACRP30headless:CD256, ACRP30headless:TNFSF13, ALTERNATE NAMES: ACRP30headless:A-proliferation-inducing Ligand: ACCESSION NO.: Q9D777 PROTEIN GI NO.: 21363035 GENE ID: 69583 Background and References APRIL is a cytokine that belongs to the TNF superfamily and binds to TACI and BCMA. It is implicated in the regulation of tumor cell growth, is involved in monocyte/macrophage- mediated immunological processes and functions as an important survival factor for plasmablasts and bone marrow plasma cells. MultimericAPRIL™ is a high activity construct BACKGROUND: in which two trimeric APRIL ligands are artificially linked via the collagen domain of ACRP30. This construct very effectively stimulates proliferation B cell. A basic amino acid sequence (QKQKKQ) close to the N-terminus of APRIL is required for binding to negatively charged sulfated glycosaminoglycan side chains of proteoglycans.
[Show full text]
Antigen-Specific Induced Foxp3 Regulatory T Cells Are Generated
Antigen-specific induced Foxp3+ regulatory T cells are generated following CD40/CD154 blockade Ivana R. Ferrer, Maylene E. Wagener, Minqing Song, Allan D. Kirk, Christian P. Larsen, and Mandy L. Ford1 Emory Transplant Center and Department of Surgery, Emory University, Atlanta, GA 30322 Edited by James P. Allison, Memorial Sloan-Kettering Cancer Center, New York, NY, and approved November 4, 2011 (received for review April 7, 2011) Blockade of the CD40/CD154 pathway potently attenuates T-cell in vivo accumulation of Treg and deletion of graft-specific ef- responses in models of autoimmunity, inflammation, and trans- fectors after CD40/CD154 blockade has not been investigated. plantation. Indeed, CD40 pathway blockade remains one of the To address these questions, we used an ovalbumin (OVA)- most powerful methods of prolonging graft survival in models of expressing transgenic mouse model (20), which allowed us to di- + + transplantation. But despite this effectiveness, the cellular and rectly track both donor-reactive CD4 and CD8 T-cell responses molecular mechanisms underlying the protective effects of CD40 simultaneously over time. Although previous studies have used pathway blockade are incompletely understood. Furthermore, the transgenic models to assess the degree of T-cell deletion after CD154/CD40 blockade (16, 21), none has systematically inter- relative contributions of deletion, anergy, and regulation have not + been measured in a model in which donor-reactive CD4+ and CD8+ rogated the impact of anti-CD154 on the kinetics of both CD4 and CD8+ T-cell deletion and acquisition of effector function. T-cell responses can be assessed simultaneously. To investigate the fi Our results indicated that although CD40/CD154 blockade alone impact of CD40/CD154 pathway blockade on graft-speci c T-cell delayed donor-reactive CD4+ and CD8+ T-cell expansion and responses, a transgenic mouse model was used in which recipients differentiation, the addition of DST was required for antigen- fi + + containing ovalbumin-speci cCD4 and CD8 TCR transgenic T specific T-cell deletion.
[Show full text]
APRIL Recombinant Protein Mouse, Rat & Swine Mbinant Protein
Reagents for Veterinary/Animal Model Research 1+1 FREE! July/August 2013 Special: APRILkkkk recombinant protein Bovine , Human , Mouse , Rat & Swine Valid until 30 August 2013 • With the purchase of a 5 µg vial of APRIL protein, you will receive a se cond 5 µg vial of the same APRIL protein at no cost. • Not valid with other specials or offers. • Limit one no cost vial per order, 5 no cost vials per customer during the period o f the special. • Note "July/August 2013 Special" on your order. Tumor necrosis factor ligand superfamily member 13 (TNFSF13) also known as a proliferation -inducing ligand (APRIL) is a member of the tumor necrosis factor ligand (TNF) ligand family. Nineteen cytokines have been identified as part of the TNF family on the basis of sequence, functional, and structural similarities. Family members include TNF beta (TNFSF1), TNF alpha (TNFSF2), Lymphotoxin beta (TNFSF3), OX40 Ligand (TNFSF4), CD4 0 Ligand (TNFSF5), Fas Ligand (TNFSF6), CD27 Ligand (TNFSF7), CD30 Ligand (TNFSF8), 4 -1BB Ligand (TNFSF9), TRAIL (TNFSF10), TRANCE/RANKL (TNFSF11), TWEAK (TNFSF12), APRIL(TNFSF13), BAFF (TNFSF13B), LIGHT (TNFSF14), TL1A/VEGI (TNFSF15), and GITR Ligand (TNF SF18). APRIL/TNFSF13 is expressed by macrophages and dendritic cells. APRIL/TNFSF13 has been shown to play a role in protecting cells from undergoing apoptosis and promoting B cell development APRIL Homology Across Species Via XXI Ottobre 1944, 11/240055 CASTENASO (BO - Italy Tel +39.051.62.40.700 – Fax +39.051.62.40.706 W. www.temaricerca.com – E. [email protected] Reagents for Veterinary/Animal Model Research Advantages of Kingfisher recombinant proteins • Produced in yeast and therefore do not have endotoxin • Naturally folded • Post-translationally modified • Highly pure • Biological activity has been confirmed by an independent laboratory Ordering informations Code Description Size Host Molecular Applications Purity Weight RP0376B-005 Recombinant Bovine 5UG YEAST 16.5 KDa ELISA Standard, and as a >95% APRIL (TNFSF13) Western Blot Control.
[Show full text]
Changing RANKL/OPG Mrna Expression in Differentiating Murine Primary Osteoblasts
451 Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts G P Thomas,SUKBaker, J A Eisman and E M Gardiner Bone and Mineral Research Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia (Requests for offprints should be addressed to G P Thomas, Bone and Mineral Research Program, Garvan Institute of Medical Research, 384 Victoria St, Sydney, New South Wales 2010, Australia; Email: [email protected]) Abstract Osteoblast–osteoclast coordination is critical in the main- RANKL were lessened in more mature cultures, however. tenance of skeletal integrity. The modulation of osteoclas- The RANKL/OPG ratio, an index of osteoclastogenic togenesis by immature cells of the osteoblastic lineage is stimulus, was therefore increased by 1,25-(OH)2D3 treat- mediated through receptor activator of NFB (RANK), ment at all stages of osteoblastic differentiation, but to a its ligand RANKL, and osteoprotegerin (OPG), a natural lesser degree in cultures after the onset of mineralisation. decoy receptor for RANKL. Here, the expression of OPG Thus the 1,25-(OH)2D3-driven increase in osteoclas- and RANKL in primary mouse osteoblastic cultures was togenic potential of immature osteoblasts appears to be investigated to determine whether the osteoclastogenic mediated by increased RANKL mRNA expression, with stimulus depended on the stage of osteoblastic differentia- mature osteoblasts having relatively decreased osteoclas- tion and the presence of the calciotrophic hormone 1,25- togenic activity due to increased OPG mRNA expression. dihydroxyvitamin D3 (1,25-(OH)2D3). These findings suggest a possible mechanism for the OPG mRNA expression was increased in osteoblastic recently proposed negative regulatory role of mature cultures after the onset of mineralisation relative to less osteoblasts on osteoclastogenesis and indicate that the mature cultures, but did not alter in response to 1,25- relative proportions of immature and mature osteoblasts in (OH)2D3 treatment.
[Show full text]
Anti-CD27 [LG.3A10] Standard Size Ab00670-22.0
Anti-CD27 [LG.3A10] Standard Size, 200 μg, Ab00670-22.0 View online Anti-CD27 [LG.3A10] Standard Size Ab00670-22.0 Isotype and Format: Hamster (Armenian) IgG, Kappa Clone Number: LG.3A10 Alternative Name(s) of Target: TNFRS7; CD27L receptor; T-cell activation antigen CD27; Tumor necrosis factor receptor superfamily member 7 UniProt Accession Number of Target Protein: P41272 Published Application(s): Activating, IP, FC, IF Published Species Reactivity: Rat, Human, Mouse Immunogen: This antibody was produced by injecting Armenian hamsters intraperitoneally with a mixture of two murine CD27 tag-expressing Armenian hamster fibroblast clones (AR0524 and AR0530) in Freund's adjuvant Specificity: This antibody is specific for mouse CD27, which, as in the human system, is largely restricted to cells of the T cell lineage, and is expressed on the great majority of both αβ and γδ T lymphocytes, and thymocytes. Application Notes: This antibody is specific for murine CD27, and has been used to assess the distribution of CD27 expression using IF, FC and IP analysis (Gravstein, 1995). Upon cross-linking, this antibody has been shown to induce a 4-fold increase in T cell proliferation in response to suboptimal stimulation with concanavalin A (Gravestein, 1995), indicating that this antibody is able to mimic ligand binding. Antibody First Published in: Gravstein et al. Novel mAbs reveal potent co-stimulatory activity of murine CD27 International immunology, April 1995, Vol.7(4), pp.551-7 PMID:7547681 Note on publication: Describes the original use of this antibody to elucidate the distribution and co- stimulatory activity of CD27. Product Form Size: 200 μg Purified antibody.
[Show full text]
Download of These Slides, Please Direct Your Browser to the Following Web Address
Clinical Roundtable Monograph Clinical Advances in Hematology & Oncology April 2014 CD30 in Lymphoma: Its Role in Biology, Diagnostic Testing, and Targeted Therapy Discussants Eduardo M. Sotomayor, MD Susan and John Sykes Endowed Chair in Hematologic Malignancies Moffitt Cancer Center Scientific Director, DeBartolo Family Personalized Medicine Institute Professor, Department of Oncologic Sciences and Pathology & Cell Biology University of South Florida College of Medicine Tampa, Florida Ken H. Young, MD, PhD Associate Professor The University of Texas MD Anderson Cancer Center Department of Hematopathology Houston, Texas Anas Younes, MD Chief of Lymphoma Service Memorial Sloan Kettering Cancer Center New York, New York Abstract: CD30, a member of the tumor necrosis factor receptor superfamily, is a transmembrane glycoprotein receptor consisting of an extracellular domain, a transmembrane domain, and an intracellular domain. CD30 has emerged as an important molecule in the field of targeted therapy because its expression is generally restricted to specific disease types and states. The major cancers with elevated CD30 expression include Hodgkin lymphoma and anaplastic large T-cell lymphoma, and CD30 expression is considered essential to the differential diagnosis of these malignancies. Most commonly, CD30 expression is detected and performed by immunohistochemical staining of biopsy samples. Alternatively, flow cytometry analysis has also been developed for fresh tissue and cell aspiration specimens, including peripheral blood and bone marrow aspirate. Over the past several years, several therapeutic agents were developed to target CD30, with varying success in clinical trials. A major advance in the targeting of CD30 was seen with the development of the antibody-drug conjugate brentuximab vedotin, which consists of the naked anti-CD30 antibody SGN-30 conjugated to the synthetic antitubulin agent monomethyl auristatin E.
[Show full text]